DCOY on Nasdaq

Decoy Therapeutics Inc.

We are a pre-clinical stage biotechnology company focused on advancing our pipeline of peptide conjugate therapeutics engineered through our proprietary IMP 3 ACT™ platform.3 From its latest annual report

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with Bio Essence Corp, Lipocine Inc. or Oramed Pharmaceuticals, or pick any stock.

  • TickerDCOY on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersHouston, Texas1
  • Incorporated inDE2
  • Business address2450 Holcombe Blvd, Suite J-608, Houston, Tx 770212
  • Filer categoryNon-accelerated filer, Smaller reporting company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

We are a pre-clinical stage biotechnology company focused on advancing our pipeline of peptide conjugate therapeutics engineered through our proprietary IMP 3 ACT™ platform. Our IMP 3 ACT™ platform represents a paradigm shift in peptide conjugate drug discovery and manufacturing, leveraging machine learning ("ML") and artificial intelligence ("AI") tools alongside high-speed synthesis techniques to rapidly engineer, optimize and manufacture peptide conjugates that target serious unmet medical needs. Peptide conjugates are emerging as a major therapeutic drug modality, with the potential to transform multiple therapeutic areas. Utilizing our novel IMP 3 ACT platform that increases the drug development speed and reduce the complexity of variant synthesis, we aim to build a robust portfolio of novel peptide conjugate therapeutics, initially focusing on infectious diseases and oncology, with…3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2022

-100.0%Revenue growth, 20224
-304.4%Return on equity5

Financial statements

Revenue674$0 in 2022
0$2.0M$4.0M$6.0M2019: $3.5M$3.5M20192020: $5.2M$5.2M2020+51%2021: $1.8M$1.8M2021−65%2022: $0$02022
Operating income6748-$31.8M in 2022+285% since 2019
-$40.0M-$30.0M-$20.0M-$10.0M02019: -$8.3M-$8.3M20192020: -$7.8M-$7.8M2020−6%2021: -$12.8M-$12.8M2021+65%2022: -$31.8M-$31.8M2022+149%
Net income6748-$31.6M in 2022+356% since 2019
-$40.0M-$30.0M-$20.0M-$10.0M02019: -$6.9M-$6.9M20192020: -$7.4M-$7.4M2020+6%2021: -$12.8M-$12.8M2021+74%2022: -$31.6M-$31.6M2022+148%

Every line of the income statement as filed: the last 2 fiscal years, latest first.11

Period ending2025-12-312024-12-31
Acquired in-process research and development$8.5M$0
Research and development$368.2K$770.0K
General and administrative$3.7M$5.0M
Total operating expenses$12.6M$5.7M
Loss from operations-$12.6M-$5.7M
Interest income and other, net$95.5K$158.5K
Net loss-$12.5M-$5.6M
Loss attributable to common stockholders-$12.5M-$5.6M
Net loss per share attributable to common stockholders - basic-$129-$70
Net loss per share attributable to common stockholders - diluted-$129-$70
Total net loss per share - basic-$129.10-$69.54
Total net loss per share - diluted-$129.10-$69.54
Weighted-average number of common shares used in net loss per share attributable to common stockholders - basic97.0K shares80.2K shares
Weighted-average number of common shares used in net loss per share attributable to common stockholders - diluted97.0K shares80.2K shares

Compare Decoy Therapeutics Inc. with another company

Leadership

Who has led Decoy Therapeutics Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Christoph H. Westphal2015–2016
  2. William K. McVicar2017–2018

President

  1. Christoph H. Westphal2015–2016
  2. Marina Hahn2015
  3. William K. McVicar2017–2018

Chief financial officer

  1. John P. McCabe2017–2018
  2. Scott Jordan2019
  3. Mark J. Rosenblum2019–now

Chief operating officer

  1. Katharine Lindemann2015–2017
20202025
Board members and other officers (26)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Chief Executive Officer, PresidentDavid J. Arthur named May 5, 2022 to Dec 27, 202445

Former names

  • Salarius Pharmaceuticals, Inc.Jul 23, 2019 to Jan 9, 20262
  • Flex Pharma, Inc.Aug 6, 2014 to Jul 22, 20192

Timeline

  1. Jul 27, 2017New chief executive William K. McVicar becomes CEO12
  2. Jan 28, 2015New chief executive Christoph H. Westphal becomes CEO13

Filings

262 filings to the SEC since October 2021: 7 annual reports, 15 quarterly reports, 75 major events, 64 insider forms, 12 large holders, 3 private raises, 86 other. The latest 20:

  1. Oct 7, 2026S-1 EDGAR
  2. Sep 23, 20268-K EDGAR
  3. Sep 15, 20268-K EDGAR
  4. Sep 2, 20264 EDGAR
  5. Sep 2, 20264 EDGAR
  6. Sep 2, 20264 EDGAR
  7. Sep 2, 20264 EDGAR
  8. Sep 2, 20264 EDGAR
  9. Sep 2, 20264 EDGAR
  10. Sep 2, 20264 EDGAR
  11. Sep 2, 20264 EDGAR
  12. Sep 2, 20264 EDGAR
  13. Sep 2, 20264 EDGAR
  14. Aug 14, 2026SCHEDULE 13G EDGAR
  15. Aug 12, 202610-Q EDGAR
  16. Aug 4, 2026DEFA14A EDGAR
  17. Aug 4, 2026DEF 14A EDGAR
  18. Jul 31, 20263 EDGAR
  19. Jul 24, 2026PRE 14A EDGAR
  20. Jul 17, 2026EFFECT EDGAR

The 262 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

11 open-market trades by officers, directors and large owners since October 2021: 10 buys and 1 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Dec 30, 2025HANISH ARNOLD CDirectorSale27$0.64$17Form 4
Nov 20, 2025HANISH ARNOLD CDirectorBuy5,000$0.75$3.8KForm 4
Nov 20, 2025Rosenblum Mark JChief Financial OfficerBuy20,000$0.80$16.0KForm 4
Jun 7, 2022Burleson TessDirectorBuy27,700$0.18$5.0KForm 4
Jun 7, 2022Lieber Jonathan IDirectorBuy37,500$0.19$7.1KForm 4
Jun 6, 2022McVicar William K.DirectorBuy26,553$0.19$5.0KForm 4
Jun 3, 2022HANISH ARNOLD CDirectorBuy28,000$0.18$5.0KForm 4
May 31, 2022Rosenblum Mark JChief Financial OfficerBuy28,000$0.18$5.0KForm 4
May 26, 2022Arthur David J.Chief Executive OfficerBuy43,900$0.18$7.9KForm 4
Mar 3, 2022Rosenblum Mark JChief Financial OfficerBuy76,246$0.39$29.7KForm 4
Mar 3, 2022Arthur David J.Chief Executive OfficerBuy139,488$0.39$54.4KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Dec 27, 2024Filed a private offering of equity Form D: $10 million offered in all Form D
  2. May 11, 2023Raised $6 million in a private offering of equity Form D: 1 investor so far Form D
  3. Apr 25, 2022Raised $2.3 million in a private offering of securities Form D: 4 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Vanguard Capital Management LLC4,034$29.0K0.0%New
Tower Research Capital LLC (TRC)256$1.8K0.0%−765
UBS Group AG25$1800.0%−521
Caitong International Asset Management Co., Ltd2$140.0%New

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53